

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., CELLTRION, INC., and
APOTEX, INC.,
Petitioners,

v.

REGENERON PHARMACEUTICALS, INC.,
Patent Owner.

Inter Partes Review No.: IPR2021-00881¹

U.S. Patent No. 9,254,338 B2
Filed: July 12, 2013
Issued: February 9, 2016
Inventor: George D. Yancopoulos

Title: USE OF A VEGF ANTAGONIST TO TREAT
ANGIOGENIC EYE DISORDERS

PETITIONER REPLY

¹ IPR2022-00258 and IPR2022-00298 have been joined with this proceeding.

TABLE OF CONTENTS

I.	INTRODUCTION.....	1
II.	PERSON OF ORDINARY SKILL IN THE ART (“POSA”).....	4
III.	CLAIM CONSTRUCTION.....	6
A.	PREAMBLE: “A METHOD FOR TREATING AN ANGIOGENIC EYE DISORDER IN A PATIENT.”	7
1.	If Limiting, The Board Should Apply Its Preamble Construction.....	7
2.	PO Reads In Multiple Unsupported and Undefined Limitations.....	7
a.	PO’s “high level of efficacy” is unsupported.....	8
b.	PO’s “high level of efficacy” is undefined (and inconsistent with the intrinsic evidence).....	10
c.	PO’s “standard of care” claim meaning also is undefined, variable and subjective.....	13
B.	“INITIAL DOSE,” “SECONDARY DOSE(S)” AND “TERTIARY DOSE(S).”	14
1.	All Are Defined As The Temporal Sequence Of Doses.....	15
2.	PO’s <i>Current</i> Construction Fundamentally Differs From Its Last Proposal For The Same Term (In The Same Family).....	16
3.	PO’s Construction Eliminates the Notice Function.....	17
IV.	ANTICIPATION AND OBVIOUSNESS.....	18
A.	THE ASSERTED REFERENCES HAVE UTILITY AND ARE NOT SUBJECT TO THE EXPERIMENTAL USE EXCEPTION.....	18
B.	THE ASSERTED REFERENCES DISCLOSE EVERY-8-WEEK VEGF TRAP-EYE ADMINISTRATION.....	21

C.	VEGF TRAP-EYE/AFLIBERCEPT WAS DISCLOSED IN EACH ASSERTED REFERENCE.	21
1.	VEGF Trap-Eye/Aflibercept sequence is a prior art, necessary feature.	22
2.	VEGF Trap-Eye/Aflibercept sequence is inherent.	23
D.	THERE WAS NEVER CONFUSION OVER THE IDENTITY OF VEGF TRAP-EYE/AFLIBERCEPT.	23
1.	“VEGF Trap-Eye” and “aflibercept” were known as the same molecular structure.	23
2.	“VEGF Trap-Eye” and “aflibercept” molecular weight reports were, in fact, <i>consistent</i>	24
3.	VEGF Trap-Eye is not a genus of proteins.	26
4.	VEGF Trap-Eye/Aflibercept was known in the prior art as VEGFR1R2-FcΔC1(a), “VEGF Trap _{R1R2} ” for short.	27
5.	PO’s confidentiality claims are irrelevant.	28
E.	VEGF TRAP-EYE/AFLIBERCEPT ADMINISTRATION RESULTED IN EFFECTIVE TREATMENT.	29
F.	THE CLAIMS WOULD HAVE BEEN OBVIOUS.	32
G.	NO EVIDENCE OF “SURPRISING” / “UNEXPECTED” RESULTS OR “LONG-FELT, UNMET NEED”.	34
H.	NO NEXUS / NO COMMERCIAL SUCCESS.	35
V.	CONCLUSION.	38

TABLE OF AUTHORITIES

Cases

<i>Abbott Lab 'ys v. Geneva Pharms., Inc.</i> , 182 F.3d 1315 (Fed. Cir. 1999).....	22
<i>Al-Site Corp. v. VSI Int'l Inc.</i> , 174 F.3d 1308 (Fed. Cir. 1999).....	4
<i>Amgen Inc. v. Alexion Pharms., Inc.</i> , IPR2019-00740, Paper 15 (P.T.A.B. Aug. 30, 2019).....	29
<i>Beckman Instruments v. LKB Produkter AB</i> , 892 F.2d 1547 (Fed. Cir. 1989).....	20
<i>Byrne v. Wood, Herron & Evans, LLP</i> , 450 F. App'x 956 (Fed. Cir. 2011).....	5
<i>Celltrion, Inc. v. Genentech, Inc.</i> , IPR2016-01667, Paper No. 15 (P.T.A.B. Mar. 2, 2017).....	31
<i>Continental Circuits LLC v. Intel Corp.</i> , 915 F.3d 788 (Fed. Cir. 2019).....	10
<i>Elan Microelectronics Corp. v. Apple, Inc.</i> , No. 09-01531, 2010 WL 4510909 (N.D. Cal. Nov. 1, 2010).....	18
<i>Ex Parte Urban Weber</i> , Appeal 2020-005142, 2021 WL 4319420 (P.T.A.B. Sept. 21, 2021).....	21
<i>Extreme Networks, Inc. v. Enterasys Networks, Inc.</i> , 395 F. App'x 709 (2010).....	6
<i>Gilead Scis., Inc. v. United States</i> , IPR2019-01455, Paper No. 16 (P.T.A.B. Feb. 5, 2020).....	31
<i>Helsinn Healthcare S.A. v. Dr. Reddy's Lab 'ys, Ltd.</i> , No. CV 14-4274 (SRC), 2018 WL 623642 (D.N.J. Jan. 30, 2018).....	19
<i>Hoffmann-La Roche Inc. v. Apotex Inc.</i> , 748 F.3d 1326 (Fed. Cir. 2014).....	32, 33, 34

<i>HVLPO2, LLC v. Oxygen Frog, LLC</i> , 949 F.3d 685 (Fed. Cir. 2020).....	6
<i>Impax Labs. Inc. v. Aventis Pharm.Inc.</i> , 468 F.3d 1366 (Fed. Cir. 2006).....	19
<i>In re Baxter Travenol Labs.</i> , 952 F.2d 388 (Fed. Cir. 1991).....	21
<i>In re Omeprazole Pat. Litig.</i> , 483 F.3d 1364 (Fed. Cir. 2007).....	21
<i>In re Omeprazole Patent Litig.</i> , 536 F.3d 1361 (Fed. Cir. 2008).....	20
<i>In Re: Copaxone Consol. Cases</i> , 906 F.3d 1013 (Fed. Cir. 2018).....	2, 7, 8
<i>Intellectual Ventures I LLC v. T-Mobile USA, Inc.</i> , 902 F.3d 1372 (Fed. Cir. 2018).....	9
<i>Kaneka Corp. v. Xiamen Kingdomway Grp. Co.</i> , 790 F.3d 1298 (Fed. Cir. 2015).....	2, 8
<i>KSR Int’l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007).....	6
<i>Merck & Co., Inc. v. Teva Pharms. USA, Inc.</i> , 395 F.3d 1364 (Fed. Cir. 2005).....	30, 36
<i>Microsoft Corp. v. Synkcloud Techs., LLC</i> , IPR2020-01316, Paper 43 (P.T.A.B. Jun. 14, 2021).....	35
<i>Nautilus, Inc. v. Biosig Instruments, Inc.</i> , 572 U.S. 898 (2014).....	17
<i>Oatey Co. v. IPS Corp.</i> , 514 F.3d 1271 (Fed. Cir. 2008).....	13, 16
<i>Paragon Podiatry Lab. v. KLM Labs. Inc.</i> , 984 F.2d 1182 (Fed. Cir. 1993).....	20

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.